Skip to content
Book an appointment

Retatrutide: encouraging findings on weight and knee pain

Two clinical trials link investigational retatrutide to substantial weight loss and less pain. Whether it protects the joint remains unknown.

Dr Dimitrios Rigopoulos 21 November 2026 3 min read
Μεγαλύτερος ενήλικας συζητά με γιατρό για τον πόνο στο γόνατο και την κίνηση.
In this article
  1. What the evidence shows
  2. How certain are the findings?
  3. Our view
  4. What this means for you

An investigational weight-loss drug, retatrutide, has shown encouraging results in people with obesity and painful knee osteoarthritis. In two clinical trials, many participants lost substantial weight and reported noticeably less pain. However, this does not yet mean that the drug prevents knee joint deterioration or avoids the need for future surgery.

What the evidence shows

The two studies included more than 1,000 participants in total. They involved adults with obesity and knee osteoarthritis, a condition involving joint deterioration that can make walking, using stairs and getting up from a chair difficult. Specific ages and the countries where patients participated are not provided; the results are not based on Greek data.

At the highest dose, average weight loss was approximately one-quarter of initial body weight. Combining the results of both trials, about 67 in every 100 people who received retatrutide reported that their pain had decreased by at least half. In the placebo group, which received treatment without the active ingredient, this occurred in 38 in every 100: a difference of about 29 people per 100.

Pain was assessed using a standardized questionnaire and a score from 0 to 10, as well as daily entries in an app. Reductions in blood pressure, blood lipids and markers of inflammation were also reported, without detailed figures in the available material.

Retatrutide is an injectable drug under investigation. It acts on three different hormone receptors, sites on cells that receive signals from hormones. Based on this announcement, it should not be presented as an already available, approved option.

How certain are the findings?

These are two phase 3 clinical trials, an advanced stage of evaluation, comparing the drug with a placebo. This gives the results greater weight than simply observing people who lose weight. The announcement mentions publication in the New England Journal of Medicine, but does not describe the duration of follow-up or provide details of how participants were assigned to the groups.

There are important limitations. People who already needed knee replacement surgery were excluded. People without excess weight were not studied. We also do not know whether the relief is mainly due to the reduced weight-related load on the knee or also to other effects of the drug.

Detailed information on adverse effects or treatment discontinuations is not provided. The announcement highlights gastrointestinal symptoms and loss of muscle mass as issues requiring attention with such treatments. Retatrutide is being developed by Eli Lilly, and company scientists were among the authors. Funding is not specified in the available text.

Our view

We believe the important finding is not just the change on the scales, but the possibility of meaningful relief in everyday life. The difference compared with placebo is encouraging. At the same time, the fact that a considerable number of people in the comparison group also improved shows why striking individual accounts are not enough.

Less pain does not mean the joint has been restored. This particular treatment has not been proven to slow joint deterioration or reduce the need for surgery. In our view, the data open up an important avenue for research, rather than providing a reason to abandon current care. Diet, appropriately adapted physical activity and maintaining muscle strength continue to have a role.

What this means for you

  • If pain limits your walking or daily activities, discuss a comprehensive management plan with your doctor.
  • If you have excess weight, seek support for sustainable changes. The material notes that even smaller weight losses, of around 5%–10%, may improve pain.
  • Discuss suitable exercise or physiotherapy, with an emphasis on supporting the knee and maintaining muscle.
  • Do not start or change medication based on a news report. An individual assessment is needed, particularly in older adults, people with chronic conditions, and during pregnancy or breastfeeding.
  • If you are already receiving weight-management treatment, tell your doctor about gastrointestinal symptoms or concerns about loss of strength, without changing the treatment yourself.

This article is for informational purposes and does not replace your doctor’s advice.

Dr Dimitrios Rigopoulos
Written by Dr Dimitrios Rigopoulos Specialist in Internal Medicine, MD, PhD, Director of the 1st Department of Internal Medicine at NIMTS Hospital, SCOPE Certified by the World Obesity Federation. Biography

This article is for information only and does not replace an examination and advice from your doctor.